MaxCyte, Inc. (NASDAQ:MXCT) Shares Sold by Lazard Asset Management LLC

Lazard Asset Management LLC lessened its position in shares of MaxCyte, Inc. (NASDAQ:MXCTFree Report) by 2.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 457,368 shares of the company’s stock after selling 13,084 shares during the quarter. Lazard Asset Management LLC owned 0.44% of MaxCyte worth $1,426,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of MXCT. Quantbot Technologies LP purchased a new position in shares of MaxCyte during the 2nd quarter valued at about $27,000. Victory Capital Management Inc. acquired a new position in MaxCyte in the third quarter valued at approximately $31,000. Johnson Investment Counsel Inc. purchased a new stake in MaxCyte in the 3rd quarter worth approximately $34,000. Tower Research Capital LLC TRC grew its stake in shares of MaxCyte by 139.8% during the 1st quarter. Tower Research Capital LLC TRC now owns 7,108 shares of the company’s stock worth $35,000 after purchasing an additional 4,144 shares during the period. Finally, Royal Bank of Canada increased its holdings in shares of MaxCyte by 80.7% during the 2nd quarter. Royal Bank of Canada now owns 9,162 shares of the company’s stock valued at $42,000 after purchasing an additional 4,091 shares in the last quarter. 62.25% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently commented on MXCT shares. Craig Hallum assumed coverage on shares of MaxCyte in a research report on Wednesday, November 29th. They set a “buy” rating and a $7.00 price target on the stock. William Blair restated an “outperform” rating on shares of MaxCyte in a research report on Tuesday.

Check Out Our Latest Analysis on MaxCyte

Insider Activity at MaxCyte

In other news, Director John Joseph Johnston sold 5,000 shares of the stock in a transaction on Friday, January 26th. The stock was sold at an average price of $5.12, for a total transaction of $25,600.00. Following the completion of the transaction, the director now directly owns 120,583 shares in the company, valued at approximately $617,384.96. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 6.00% of the company’s stock.

MaxCyte Stock Performance

NASDAQ:MXCT opened at $3.94 on Friday. The stock has a market capitalization of $410.15 million, a PE ratio of -10.65 and a beta of 1.36. MaxCyte, Inc. has a fifty-two week low of $2.45 and a fifty-two week high of $5.55. The company has a fifty day moving average of $4.83 and a two-hundred day moving average of $4.14.

About MaxCyte

(Free Report)

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.

Recommended Stories

Institutional Ownership by Quarter for MaxCyte (NASDAQ:MXCT)

Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.